Although many regimens have been used for PDAC treatment, the combination of the epidermal growth factor receptor (EGFR) inhibitor, erlotinib with gemcitabine has been the only molecular targeted drug tested so far which has been superior to gemcitabine alone.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death in Japan and worldwide, with a 5-yr survival rate of less than 5% for all stages combined 1, 2, 3 . Most patients are already unresectable when diagnosed and even after successful resection the cancers frequently relapse. In addition, PDAC is highly resistant to conventional chemotherapy regimens. Although molecular targeted drugs have been extensively evaluated in a number of clinical trials, EGFR inhibitor erlotinib in combination with gemcitabine was the only regimen using molecular target agents that showed prolonged survival compared to gemcitabine alone 4 . The impact of clinical benefit previously reported appears relatively small, however, considering that almost no regimens have shown any statistically significant benefits compared to gemcitabine in PDAC, this is one of the important options in this field. Moreover, erlotinib has just been approved by the government in Japan as a formal regimen for the treatment of PDAC Therefore, understanding the detailed mechanisms whereby erlotinib shows an efficacy on PDAC in combination with gemcitabine is gaining more significance.
The predictive factors for treatment with EGFR inhibitor have been established in some cancers. In metastatic colorectal cancer, EGFR inhibition benefits only the KRAS-wild type patients 5, 6 . In non-small cell lung cancer (NSCLC), patients with Author Manuscript Published OnlineFirst on February 1, 2013; DOI: 10.1158/0008-5472. CAN-12-1453 activating EGFR mutation have shown better response and survival 7, 8 . With regard to PDAC, previous studies reported that the overall rate of EGFR expression was 30-70% 9, 10 and no obvious impact of EGFR expression on outcome was observed 4, 10 . Activating EGFR mutations have rarely been reported in human PDAC. Moreover, since a majority of PDAC patients carry downstream KRAS mutations 11, 12 , it is difficult to explain why upstream EGFR inhibition has a beneficial effect on the PDAC.
Recently, by using pancreas-specific conditional activation or knockout of clinically relevant PDAC-related genes and signaling pathways, genetically engineered murine PDAC progression models have been described [13] [14] [15] [16] [17] . Previous studies reported that the genetically-engineered models can recapitulate clinical tumor microenvironment better than xenograft tumor models and also can recapitulate the survival effect of clinical trials of human patients 18, 19 .
We have already established pancreas-specific TGF-beta receptor II (Tgfbr2) knockout mice in the context of Kras activation (Kras G12D +Tgfbr2 KO ) 13 . The clinical and histopathological manifestations of the mice recapitulated human PDAC. This model histologically demonstrates differentiated ductal adenocarcinoma with abundant stromal components including desmoplastic reaction, but not sarcomatoid or undifferentiated tumors, which are rare in human pancreatic cancer and were reported in other genetically-engineered models 13 . With regard to TGF-β signaling, SMAD4 gene mutation or deletion is frequently observed in human PDAC patients 20 , however, mice containing Smad4 knockout with the Kras activation in the pancreas was reported to demonstrate cystic tumors of the pancreas, distinct precancer lesions from PanIN, intraductal papillary mucinous neoplasm, or mucious cystic neoplasm [21] [22] [23] ．Therefore, our Kras G12D +Tgfbr2 KO might be the closest approximation of the human PDAC in terms of histology, that can be expected to recapitulate response to the therapy.
In the present study we investigated the mode of action of gemcitabine and erlotinib in vivo using the Kras G12D +Tgfbr2 KO model and propose mechanisms explaining why PDAC with extremely frequent KRAS mutation benefits from the EGFR inhibitor in combination with gemcitabine.
are described in Supplementary Methods.
Quantitative RT-PCR.
Details are described in Supplementary Methods.
ELISA
The cells were treated with vehicle or gemcitabine (10 nM) for 24 h in serum-containing media and cell culture media were centrifuged at 2000 rpm for 10 min at 4℃ and the supernatants were subjected to the ELISA (Ray Biotech, Inc). Pancreatic tumors from the treated mice were homogenized with lysis buffer (Raybiotech, Inc) and centrifuged at 15000 G for 15 min at 4℃and the supernatants were also subjected to the ELISA.
Flow cytometry.
The cells suspended in PBS were incubated in propidium iodide solution (Dojindo Laboratories, 50 μg/mL in PBS) for 30 min. The cells were then analyzed for cell cycle status using the Guava EasyCyte Plus (Guava Technologies). Annexin assay (Guava annexin kit; Millipore) was performed according to the manufacture's protocol. 
Phospho-RTK antibody array
Mouse phospho-receptor-type tyrosine kinase (RTK) antibody array (R&D Systems) analysis was performed according to the manufacturer's instructions. 250 μg of lysates from the treated PDAC tissues at 7 weeks of age were subjected to analysis. The densitometric data after subtraction of background density were normalized by those of positive controls on each membrane and compared between the treatment groups.
Histology and immunohistochemsitry
Mouse tissue was harvested and processed as described previously 13 . The slides with hematoxylin & eosin staining were subjected to histological analysis. Immunohistochemistry was performed as described previously 28 . Details are described in Supplementary Methods.
Statistical Analysis
Except when indicated, quantitative data were shown as mean + SD and the two-sided Student's t test was used for statistical analysis, with P < 0.05 taken as significant. The IC50 and the combination index (CI) indicating the interaction of the drugs 
Results
Erlotinib inhibits the Kras G12D +Tgfbr2 KO PDAC progression and prolongs survival of the PDAC mice in combination with gemcitabine.
We first evaluated the survival of the Kras G12D +Tgfbr2 KO vehicle-treated PDACs ( Figure 1C, D) , although the difference did not reach a statistical significance (p = 0.092). There was no metastasis at 7 weeks of age in this mouse model. H&E staining showed that the Kras G12D +Tgfbr2 KO PDAC tissues were basically well-differentiated ductal adenocarcinoma with rich stromal components and also contained poorly-differentiated and invasive ductal adenocarcinoma ( Figure 1E ). The quantification of remaining normal pancreas area confirmed a statistical difference between the gemcitabine + erlotinib group and the control group, as well as the gemcitabine + erlotinib group and the gemcitabine group ( Figure 1F ). The tumor area on the microscope was almost consistent with that judged macroscopically. There were no apparent pathological differences such as grade of malignancy between tumor tissues with or without gemcitabine, whereas gemcitabine + erlotinib-treated PDACs were less frequent poorly-differentiated PDAC ( Figure 1E ).
Erlotinib inhibits the growth and intracellular signaling of PDAC cells in vitro. Gemcitabine activates the phosphorylation of Egfr and Erk, which is inhibited by adding erlotinib in the Kras G12D +Tgfbr2 KO PDAC in vivo.
We sacrificed the mice at 7 weeks of age and evaluated the effect of gemcitabine and erlotinib on signal transduction.
Immunohistochemistry showed that Egfr and Erk were strongly phosphorylated in the control group and gemcitabine treatment increased the phosphorylation of Egfr and Erk. Erlotinib in combination with gemcitabine inhibited the activation of Egfr and Erk. Table S1 ). In mouse PDAC cells we detected that gemcitabine alone activated phosphorylation of Erk and Mek, which was inhibited by adding erlotinib ( Figure 4C ). The gemcitabine-induced Erk phosphorylation was observed in a time-dependent manner for 0 to 24 h ( Figure 4D ).
We also examined the intracellular signaling of mouse pancreatic fibroblasts were significantly elevated and Amphiregulin also seemed to be elevated after gemcitabine treatment, whereas in the murine fibroblast K643f gemcitabine didn't affect the expression of Egfr ligands ( Figure 5A ). In the human PDAC cells (Capan-1, CFPAC-1), Amphiregulin, TGF-α, and EGF were all significantly elevated after gemcitabine treatment ( Figure 5B ).
Next, we performed ELISA assays for EGFR ligands. In murine PDAC lysates, Amphiregulin and Egf were significantly elevated in gemcitabine-treated PDACs compared to vehicle-treated ones ( Figure 5C ). In the human PDAC cells (BxPC-3), Amphiregulin and TGF-α were significantly elevated after gemcitabine treatment. TGF-α was also significantly elevated after gemcitabine treatment in Capan-1 and CFPAC-1( Figure 5D and data not shown). Thus, the EGFR ligands upregulation can explain the gemcitabine-induced EGFR-ERK activation.
We observed that gemcitabine induced the PDAC cell apoptosis and adding EGF reduced the apoptosis in flow cytometry, which suggested that the gemcitabine-induced EGFR ligands upregulation might be associated with anti-apoptotic response of the PDAC cells against gemcitabine ( Figure S1 ). There might be release of EGFR ligands from dying 
cells by chemotherapy, however, we observed the upregulation of the ligands at mRNA levels, which indicated that the response was derived from live PDAC cells.
Gemcitabine induces activation of Erbb2 in the Kras G12D +Tgfbr2 KO PDAC mouse model.
We assessed whether receptor-type tyrosine kinases (RTKs) other than EGFR were activated in response to gemcitabine by using a phospho-RTK antibody array, which contained 39 RTKs. We compared four groups of mouse pancreatic tissue lysates;
vehicle-treated, gemcitabine-treated with low Egfr expression, gemcitabine-treated with high Egfr expression, and gemcitabine + erlotinib-treated. The Egfr phosphorylation in the gemcitabine-treated group with high Egfr expression was inhibited in combination with erlotinib. Most notably, phospho-Erbb2 was more strongly induced than phospho-Egfr in gemcitabine-treated group and was almost completely inhibited in combination with erlotinib ( Figure 6A, B) . The array also showed Erbb4 induction by gemcitabine, which was also inhibited by adding erlotinib (Figure 6A, B) .
We evaluated this result by immunoblot analysis. The expression and phosphorylation of Erbb2 were found to be increased in the gemcitabine-treated mice and adding erlotinib inhibited the induction ( Figure 6C ). The Erbb2 expression pattern was also confirmed by immunohistochemistry ( Figure 6D ).
Research. 
We observed that gemcitabine treatment increased the total protein level and phosphorylation of Erbb2, which was inhibited by adding erlotinib in the PDAC cells in vitro ( Figure 7A In this study, we demonstrate one of the mechanisms by which the EGFR inhibitor, erlotinib, inhibits PDAC with extremely frequent KRAS mutation. Although EGFR overexpression has been reported as a common feature of PDAC (30-70%) 9,10 , activating EGFR mutations have rarely been reported, and EGFR gene copy number and KRAS mutational status were not found to be predictive markers of a survival benefit from EGFR inhibitor 9 . The human PDAC and lung cancer cells used in this study had no EGFR mutations. We showed that gemcitabine induced activation of EGFR and ErbB2 as well as downstream MAPK signal activation, which was completely inhibited by adding erlotinib even in the KRAS-mutant PDAC cells. This phenomenon was commonly seen in the PDAC cells irrespective of gemcitabine sensitivity or KRAS mutation status and was also common 
erlotinib inhibited many downstream pathways of EGFR other than MAPK signaling, which could be the difference between these two drugs ( Figure 8 ).
ErbB2 is a well-known prognostic factor and therapeutic target in breast and gastric cancers. Overexpression and amplification of ErbB2 is observed in 20-30% of breast cancer 37.38 , and in 7-34% of gastric cancer [40] [41] [42] . Trastuzumab, a monoclonal antibody against ErbB2, has a survival benefit in ErbB2-positive breast cancer 39 and gastric cancer 43 . In PDAC, ErbB2 overexpression is observed (10-82%), but does not correlate with poor prognosis [44] [45] [46] . Although the antitumor effect of trastuzumab was documented in patients with high ErbB2 expression 47 , survival effects of ErbB2 inhibitor in PDAC was not significant in clinical trials 48 . The true clinical advantage of ErbB2-targeted therapy in PDAC therefore remains unclear.
We observed that the Kras G12D +Tgfbr2 KO PDAC showed a better survival response to the gemcitabine plus erlotinib compared to the result of human clinical trial 4 . The suggested mechanism involved ErbB2. In addition, murine PDAC with high Egfr expression occupied the entire pancreas following gemcitabine-alone treatment, while PDAC with low Egfr expression showed frequent normal pancreas (Figures 1, 3, 6 ). Taken together, it might be possible that certain subpopulation of PDAC patients, e.g., with disrupted TGF-β signaling and high EGFR expression, can especially have the survival benefit from EGFR/ErbB2-targeted therapy.
Research. CAN-12-1453 Since the Kras G12D +Tgfbr2 KO PDAC contained abundant stromal components similar to human PDAC, we also tried to clarify the effects of erlotinib on the tumor microenvironment, such as fibroblasts, neutrophils and macrophages. Gemcitabine and erlotinib didn't affect the intracellular signaling of pancreatic fibroblasts in vitro and no prominent differences were detected in immunohistochemistry of neutrophil and macrophage in the treated PDAC tissues. Thus, we concluded that erlotinib's major effect is on EGFR-MAPK signaling in PDAC cells rather than the stromal cells.
In conclusion, the Kras G12D +Tgfbr2 KO PDAC recapitulates chemosensitivity of human PDAC and was useful in the investigation of efficacy and mode of action of therapeutic agents, which might provide important insights into the predictive markers, beneficial drug combinations and also beneficial patient subpopulation. We found the underlying mechanisms explaining why PDAC with highly frequent KRAS mutation benefits from erlotinib in combination with gemcitabine in vitro and in vivo. Gemcitabine induced EGFR-MAPK signal activation, which was dramatically diminished by adding erlotinib even in the Kras-mutant PDAC. PDAC with high EGFR and ErbB2 expression as well as disrupted TGF-β signaling might be the beneficial subpopulation for this combination therapy. Further translational research using genetically-engineered mouse models such as the one used in this study might accelerate our understanding and 
